261 related articles for article (PubMed ID: 24259290)
1. Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis.
Petrilli A; Bott M; Fernández-Valle C
Oncotarget; 2013 Dec; 4(12):2354-65. PubMed ID: 24259290
[TBL] [Abstract][Full Text] [Related]
2. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2.
Petrilli A; Copik A; Posadas M; Chang LS; Welling DB; Giovannini M; Fernández-Valle C
Oncogene; 2014 Jul; 33(27):3571-82. PubMed ID: 23934191
[TBL] [Abstract][Full Text] [Related]
3. Generation and Use of Merlin-Deficient Human Schwann Cells for a High-Throughput Chemical Genomics Screening Assay.
Petrilli AM; Fernández-Valle C
Methods Mol Biol; 2018; 1739():161-173. PubMed ID: 29546707
[TBL] [Abstract][Full Text] [Related]
4. Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells.
Fuse MA; Plati SK; Burns SS; Dinh CT; Bracho O; Yan D; Mittal R; Shen R; Soulakova JN; Copik AJ; Liu XZ; Telischi FF; Chang LS; Franco MC; Fernandez-Valle C
Mol Cancer Ther; 2017 Nov; 16(11):2387-2398. PubMed ID: 28775147
[TBL] [Abstract][Full Text] [Related]
5. Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.
Yang C; Asthagiri AR; Iyer RR; Lu J; Xu DS; Ksendzovsky A; Brady RO; Zhuang Z; Lonser RR
Proc Natl Acad Sci U S A; 2011 Mar; 108(12):4980-5. PubMed ID: 21383154
[TBL] [Abstract][Full Text] [Related]
6. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.
Wong HK; Shimizu A; Kirkpatrick ND; Garkavtsev I; Chan AW; di Tomaso E; Klagsbrun M; Jain RK
Neoplasia; 2012 Feb; 14(2):84-94. PubMed ID: 22431917
[TBL] [Abstract][Full Text] [Related]
7. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
Petrilli AM; Garcia J; Bott M; Klingeman Plati S; Dinh CT; Bracho OR; Yan D; Zou B; Mittal R; Telischi FF; Liu XZ; Chang LS; Welling DB; Copik AJ; Fernández-Valle C
Oncotarget; 2017 May; 8(19):31666-31681. PubMed ID: 28427224
[TBL] [Abstract][Full Text] [Related]
8. A neuronal function of the tumor suppressor protein merlin.
Schulz A; Zoch A; Morrison H
Acta Neuropathol Commun; 2014 Jul; 2():82. PubMed ID: 25012216
[TBL] [Abstract][Full Text] [Related]
9. CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells.
Huegel J; Dinh CT; Martinelli M; Bracho O; Rosario R; Hardin H; Estivill M; Griswold A; Gultekin S; Liu XZ; Fernandez-Valle C
Oncotarget; 2022; 13():890-904. PubMed ID: 35875610
[TBL] [Abstract][Full Text] [Related]
10. PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2).
Hawley E; Gehlhausen J; Karchugina S; Chow HY; Araiza-Olivera D; Radu M; Smith A; Burks C; Jiang L; Li X; Bessler W; Masters A; Edwards D; Burgin C; Jones D; Yates C; Clapp DW; Chernoff J; Park SJ
Hum Mol Genet; 2021 Aug; 30(17):1607-1617. PubMed ID: 34075397
[TBL] [Abstract][Full Text] [Related]
11. Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.
Truong K; Ahmad I; Jason Clark J; Seline A; Bertroche T; Mostaert B; Van Daele DJ; Hansen MR
Neuroscience; 2018 Mar; 374():205-213. PubMed ID: 29408605
[TBL] [Abstract][Full Text] [Related]
12. Cellular mechanisms of heterogeneity in NF2-mutant schwannoma.
Chiasson-MacKenzie C; Vitte J; Liu CH; Wright EA; Flynn EA; Stott SL; Giovannini M; McClatchey AI
Nat Commun; 2023 Mar; 14(1):1559. PubMed ID: 36944680
[TBL] [Abstract][Full Text] [Related]
13. NF2: the wizardry of merlin.
Xiao GH; Chernoff J; Testa JR
Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860
[TBL] [Abstract][Full Text] [Related]
14. Cellular prion protein (PrP
Provenzano L; Ryan Y; Hilton DA; Lyons-Rimmer J; Dave F; Maze EA; Adams CL; Rigby-Jones R; Ammoun S; Hanemann CO
Oncogene; 2017 Nov; 36(44):6132-6142. PubMed ID: 28692055
[TBL] [Abstract][Full Text] [Related]
15. Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways.
Angelo LS; Wu JY; Meng F; Sun M; Kopetz S; McCutcheon IE; Slopis JM; Kurzrock R
Mol Cancer Ther; 2011 Nov; 10(11):2094-103. PubMed ID: 21903608
[TBL] [Abstract][Full Text] [Related]
16. Functional analysis of neurofibromatosis 2 (NF2) missense mutations.
Gutmann DH; Hirbe AC; Haipek CA
Hum Mol Genet; 2001 Jul; 10(14):1519-29. PubMed ID: 11448944
[TBL] [Abstract][Full Text] [Related]
17. A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2.
Petrilli AM; Fuse MA; Donnan MS; Bott M; Sparrow NA; Tondera D; Huffziger J; Frenzel C; Malany CS; Echeverri CJ; Smith L; Fernández-Valle C
Am J Transl Res; 2014; 6(5):471-93. PubMed ID: 25360213
[TBL] [Abstract][Full Text] [Related]
18. Role of Merlin/NF2 inactivation in tumor biology.
Petrilli AM; Fernández-Valle C
Oncogene; 2016 Feb; 35(5):537-48. PubMed ID: 25893302
[TBL] [Abstract][Full Text] [Related]
19. Interaction between two isoforms of the NF2 tumor suppressor protein, merlin, and between merlin and ezrin, suggests modulation of ERM proteins by merlin.
Meng JJ; Lowrie DJ; Sun H; Dorsey E; Pelton PD; Bashour AM; Groden J; Ratner N; Ip W
J Neurosci Res; 2000 Nov; 62(4):491-502. PubMed ID: 11070492
[TBL] [Abstract][Full Text] [Related]
20. G6PD and ACSL3 are synthetic lethal partners of NF2 in Schwann cells.
Kyrkou A; Valla R; Zhang Y; Ambrosi G; Laier S; Müller-Decker K; Boutros M; Teleman AA
Nat Commun; 2024 Jun; 15(1):5115. PubMed ID: 38879607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
